Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 6
2002 1
2003 11
2004 9
2005 10
2006 14
2007 13
2008 20
2009 16
2010 18
2011 8
2012 9
2013 12
2014 13
2015 10
2016 7
2017 5
2018 3
2019 8
2020 9
2021 6
2022 9
2023 7
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
Stalmans I, Lim KS, Oddone F, Fichtl M, Belda JI, Hommer A, Laganovska G, Schweitzer C, Voykov B, Zarnowski T, Holló G. Stalmans I, et al. Graefes Arch Clin Exp Ophthalmol. 2024 Jan;262(1):179-190. doi: 10.1007/s00417-023-06192-0. Epub 2023 Aug 24. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 37615697 Free PMC article. Clinical Trial.
PURPOSE : To compare the efficacy and safety of the fixed-dose combination (FDC) of netarsudil 0.02%/latanoprost 0.005% ophthalmic solution (NET/LAT; Roclanda()) with bimatoprost 0.03%/timolol maleate 0.5% (BIM/TIM; Ganfort()) ophthalmic solution in the treatment of open-a …
PURPOSE : To compare the efficacy and safety of the fixed-dose combination (FDC) of netarsudil 0.02%/latanoprost 0.005% ophthalmic solution …
Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies.
Weinreb RN, Bacharach J, Brubaker JW, Medeiros FA, Bejanian M, Bernstein P, Robinson MR. Weinreb RN, et al. J Ocul Pharmacol Ther. 2023 Jan-Feb;39(1):55-62. doi: 10.1089/jop.2022.0137. Epub 2022 Nov 15. J Ocul Pharmacol Ther. 2023. PMID: 36378864 Free PMC article. Clinical Trial.
Purpose: To evaluate the time course of biodegradation of an intracameral, biodegradable, sustained-release bimatoprost implant that lowers intraocular pressure without the need for daily eye drops. ...The implant was predominantly located inferiorly in the iridocorneal an …
Purpose: To evaluate the time course of biodegradation of an intracameral, biodegradable, sustained-release bimatoprost implant that …
Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, Wormald R, Dickersin K. Li T, et al. Ophthalmology. 2016 Jan;123(1):129-40. doi: 10.1016/j.ophtha.2015.09.005. Epub 2015 Oct 31. Ophthalmology. 2016. PMID: 26526633 Free PMC article. Review.
The mean reductions (95% credible intervals) in IOP in millimeters of mercury at 3 months ordered from the most to least effective drugs were as follows: bimatoprost 5.61 (4.94; 6.29), latanoprost 4.85 (4.24; 5.46), travoprost 4.83 (4.12; 5.54), levobunolol 4.51 (3.85; 5.2 …
The mean reductions (95% credible intervals) in IOP in millimeters of mercury at 3 months ordered from the most to least effective drugs wer …
The efficacy of bimatoprost ophthalmic solution combined with NB-UVB phototherapy in non-segmental and segmental vitiligo: a single-blind randomized controlled study.
Silpa-Archa N, Likittanasombat S, Apinuntham C, Pruksaeakanan C, Charoenpipatsin N, Chaiyabutr C, Wongpraparut C. Silpa-Archa N, et al. Sci Rep. 2023 Apr 20;13(1):6438. doi: 10.1038/s41598-023-32591-8. Sci Rep. 2023. PMID: 37081101 Free PMC article. Clinical Trial.
Bimatoprost ophthalmic solution 0.03% (PGF2alpha analogues) combined with narrowband ultraviolet B (NB-UVB) was reported to be an effective treatment for vitiligo. To investigate the efficacy and safety of treatment for non-segmental/segmental vitiligo compared among bi
Bimatoprost ophthalmic solution 0.03% (PGF2alpha analogues) combined with narrowband ultraviolet B (NB-UVB) was reported to be an eff
Fixed-combination treatments for intraocular hypertension in Chinese patients - focus on bimatoprost-timolol.
Fang Y, Ling Z, Sun X. Fang Y, et al. Drug Des Devel Ther. 2015 May 13;9:2617-25. doi: 10.2147/DDDT.S80338. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 25999695 Free PMC article. Review.
Fixed-combination drops, particularly PGA-based fixed combinations, have recently been developed and used in patients with progression or who have failed to achieve their target IOPs. Here, we reviewed the current literature on the use of bimatoprost-timolol fixed combinat …
Fixed-combination drops, particularly PGA-based fixed combinations, have recently been developed and used in patients with progression or wh …
Bimatoprost sustained-release intracameral implant reduces episcleral venous pressure in dogs.
Lee SS, Burke J, Shen J, Almazan A, Orilla W, Hughes P, Zhang J, Li H, Struble C, Miller PE, Robinson MR. Lee SS, et al. Vet Ophthalmol. 2018 Jul;21(4):376-381. doi: 10.1111/vop.12522. Epub 2018 Feb 19. Vet Ophthalmol. 2018. PMID: 29457333 Clinical Trial.
OBJECTIVE: To determine the effect of a bimatoprost sustained-release intracameral implant (Bimatoprost SR) on episcleral venous pressure (EVP) in normal dogs. ...RESULTS: Baseline mean EVP was 10.0 mmHg in the Bimatoprost SR group and 10.4 mmHg in the sham g …
OBJECTIVE: To determine the effect of a bimatoprost sustained-release intracameral implant (Bimatoprost SR) on episcleral veno …
Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis.
Carruthers J, Beer K, Carruthers A, Coleman WP 3rd, Draelos ZD, Jones D, Goldman MP, Pucci ML, VanDenburgh A, Weng E, Whitcup SM. Carruthers J, et al. Dermatol Surg. 2016 May;42(5):608-17. doi: 10.1097/DSS.0000000000000755. Dermatol Surg. 2016. PMID: 27124878 Free PMC article. Clinical Trial.

RESULTS: At Month 7, the proportion of subjects with improvement was significantly higher in bimatoprost groups versus vehicle (both, p < .001). Improvements occurred in both bimatoprost groups versus vehicle after Month 1 and continued through follow-up; eyebrow

RESULTS: At Month 7, the proportion of subjects with improvement was significantly higher in bimatoprost groups versus vehicle (both, …
Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment of evidence quality.
Gupta AK, Bamimore MA, Foley KA. Gupta AK, et al. J Dermatolog Treat. 2022 Feb;33(1):62-72. doi: 10.1080/09546634.2020.1749547. Epub 2020 Apr 13. J Dermatolog Treat. 2022. PMID: 32250713 Review.
We identified the following treatments for male AGA in decreasing rank of efficacy: platelet-rich plasma (PRP), low-level laser therapy (LLLT), 0.5 mg dutasteride, 1 mg finasteride, 5% minoxidil, 2% minoxidil, and bimatoprost. For female AGA the following were identified i …
We identified the following treatments for male AGA in decreasing rank of efficacy: platelet-rich plasma (PRP), low-level laser therapy (LLL …
Bimatoprost 0.03% Solution for the Treatment of Nonfacial Vitiligo.
Grimes PE. Grimes PE. J Drugs Dermatol. 2016 Jun 1;15(6):703-10. J Drugs Dermatol. 2016. PMID: 27272076 Clinical Trial.
Bimatoprost 0.03% ophthalmic solution showed efficacy in the treatment of vitiligo in one small study....<br /> METHODS: This randomized, double-blind, controlled study was conducted over a 20-week treatment period. Patients were randomized to 1 of 3 treatment groups
Bimatoprost 0.03% ophthalmic solution showed efficacy in the treatment of vitiligo in one small study....<br /> METHODS: This r
Treatments for alopecia areata: A systematic review and network meta-analysis.
Fukumoto T, Fukumoto R, Magno E, Oka M, Nishigori C, Horita N. Fukumoto T, et al. Dermatol Ther. 2021 May;34(3):e14916. doi: 10.1111/dth.14916. Epub 2021 Mar 4. Dermatol Ther. 2021. PMID: 33631058
Pentoxifylline plus topical corticosteroids had the highest treatment success rate compared with "no treatment," followed by pentoxifylline alone, topical calcipotriol plus narrowband ultraviolet radiation B phototherapy, topical calcipotriol, intralesional corticosteroids, syste …
Pentoxifylline plus topical corticosteroids had the highest treatment success rate compared with "no treatment," followed by pentoxifylline …
201 results